Drugs / YS247
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07583160 | Jun 2026 → Jun 2028 expected | castration-resistant prostate carcinoma | Changhai Hospital | Enrolling by invitation | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07678138 | Jun 2026 → Nov 2027 expected | glioblastoma | Huanhu Hospital Affiliated to Tianjin Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07455071 | Mar 2026 → Sep 2027 expected | — | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YS247 | “This is a phase I, single-center, open-label, dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of an autologous neoantigen-pulsed dendritic...” NCT07583160 ↗ |
| Modality | Cell therapy | “tumor neoantigen-pulsed autologous dendritic cell injection (YS247)” NCT07455071 ↗ |
| Route | Subcutaneous | “YS247 will be administered subcutaneously” NCT07678138 ↗ |